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being performed in low dose rates. The MU used for the FFF 
plans are higher in the Varian/Novalis-Eclipse combination; 
this is not seen for Elekta –Pinnacle. In general Eclipse used 
more MU than Pinnacle. The beam-on times are significantly 
reduced and the largest gain is seen for Elekta-Pinnacle. 
 
 
Conclusions: FFF can be used for SBRT planning and delivery 
of accurate dose, independent of the specific combination of 
accelerator vendor and treatment planning system. The 
different combinations have different specific issues. Future 
perspective is to add the TomoTherapy-Hi Art combination to 
the study. 
   
 
Proffered Papers: Clinical 2: Breast  
 
 
OC-0387   
The UK HeartSpare Study (Stage II): Multicentre evaluation 
of a voluntary breath-hold technique 
F.R. Bartlett1, E.M. Donovan2, H.A. McNair1, L. Corsini3, C. 
Griffin4, R.M. Colgan2, J.S. Haviland4, P.M. Evans5, J.R. 
Yarnold6, A.M. Kirby1 
1The Royal Marsden Hospital, Department of Radiotherapy, 
Sutton, United Kingdom  
2The Royal Marsden Hospital, Department of Physics, Sutton, 
United Kingdom 
3The Royal Marsden Hospital, Department of Radiotherapy, 
Fulham, United Kingdom  
4The Institute of Cancer Research, Clinical Trials and 
Statistics Unit, Sutton, United Kingdom  
5The University of Surrey, Faculty of Engineering and 
Physical Sciences, Guildford, United Kingdom  
6The Institute of Cancer Research, Division of Radiotherapy 
and Imaging, Sutton, United Kingdom  
 
Purpose/Objective: To confirm the heart-sparing ability and 
feasibility of the voluntary breath-hold (VBH) technique in a 
multicentre setting. 
Materials and Methods: Following surgery for early breast 
cancer, patients with any heart inside the 50% isodose on 
free-breathing radiotherapy planning-CT scans with standard 
tangential fields, underwent a second planning-CT scan using 
the VBH technique. Separate radiotherapy treatment plans 
were prepared based on free-breathing and VBH CT scans. 
Mean heart, left anterior descending coronary artery (LAD) 
and lung doses were calculated for each plan. Daily 
electronic portal imaging (EPI) was performed and 
scanning/treatment times were recorded. The primary 
endpoint was the percentage of patients who achieved a 
reduction in mean heart dose with VBH. Population 
systematic (Σ) and random errors (σ) were estimated and 
within-patient comparisons between techniques used 
Wilcoxon signed-rank tests. 
Results: 101 patients from 10 UK centres were recruited. 
Data for the first 43 patients has been analysed and showed 
that 41 (95%) achieved a reduction in mean heart dose with 
VBH. Mean cardiac doses (Gy) for free-breathing and VBH 
techniques were: heart 1.9 and 1.1, LAD 12.1 and 5.7, 
maximum LAD dose 34.5 and 24.8. Pooled EPI-based 
displacement data showed Σ of 1.2-1.7mm and σ 1.6-2.1mm. 
Median CT and treatment session times were 20 and 22 
minutes respectively. 
Conclusions: Preliminary data suggest multicentre 
implementation of VBH is both effective at heart-sparing and 
feasible. Results from the remaining 58 patients are being 
analysed, and complete data (including inter-centre 
comparisons) will be presented in April 2015. 
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Purpose/Objective:  
Background 
Adjuvant radiotherapy reduces the risk of recurrence and 
death for early-stage breast cancer. However in planning 
radiotherapy, dose to the heart should be considered since 
recent data suggest an increasing risk of ischemic heart 
disease with increasing dose to the heart. Conduction 
abnormalities have been reported after mediastinal radiation 
for Hodgkin’s disease, but the risk of conduction disorders 
and arrhythmias does not appear to be increased subsequent 
to breast cancer radiotherapy. Such conduction abnormalities 
constitute a quite heterogenous group covering mild as well 
as severe disorders.  
Purpose 
The aim of this study was to examine the risk of severe 
conduction abnormalities evaluated by implantation of a 
pacemaker, subsequent to breast cancer radiotherapy. 
Materials and Methods: From the database of the Danish 
Breast Cancer Collaborative Group, we identified women 
treated with radiotherapy for early-stage breast cancer in 
Denmark from 1982 to 2005. By record linkage to the Danish 
Pacemaker and ICD Registry information was retrieved on 
pacemaker implants subsequent to radiotherapy. The rate 
ratios (RR) of pacemaker implantation were estimated by 
Poisson regression for left versus right sided breast cancer 
with stratification for calendar year of breast cancer 
diagnosis, age at diagnosis and time since diagnosis (all in 
five-year groups). 95% confidence intervals (CI) and two-sides 
significance tests were calculated.  
Results: Among 18,129 women treated with radiotherapy for 
early-stage breast cancer, 179 women had a pacemaker 
implanted subsequent to radiotherapy, 90 in 9,315 left sided 
and 89 in 8,993 right sided breast cancers. The unadjusted RR 
was 1.02 (0.76-1.36 95% CI, p=0.91) and the RR adjusted for 
year, age and time since diagnosis was 1.06 (0.79-1.42 95% 
CI, p=0.71). 
Conclusions: Adjuvant radiotherapy as practiced in Denmark 
for early stage breast cancer does not increase the risk of 
severe conduction abnormalities in the heart.  
   
